Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.

Leukemia - 1 May 2023

Mauro Michael J, Hughes Timothy P, Kim Dong-Wook, Rea Delphine, Cortes Jorge E, Hochhaus Andreas, Sasaki Koji, Breccia Massimo, Talpaz Moshe, Ottmann Oliver, Minami Hironobu, Goh Yeow Tee, DeAngelo Daniel J, Heinrich Michael C, Gómez-García de Soria Valle, le Coutre Philipp, Mahon Francois-Xavier, Janssen Jeroen J W M, Deininger Michael, Shanmuganathan Naranie, Geyer Mark B, Cacciatore Silvia, Polydoros Fotis, Agrawal Nithya, Hoch Matthias, Lang Fabian

Abstract excerpt

Asciminib is approved for patients with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (CML-CP) who received ≥2 prior tyrosine kinase inhibitors or have the T315I mutation. We report updated results of a phase 1, open-label, nonrandomized trial (NCT02081378) assessing the safety, tolerability, and antileukemic activity of asciminib monotherapy 10-200 mg once or twice daily in 115 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Fusion Proteins, bcr-abl

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Neutropenia

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 36949155
DOI: 10.1038/s41375-023-01860-w
PMCID: PMC10169635

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.PMID 36949155Read ↗

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.Semantic proximity Read ↗

FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.Semantic proximity Read ↗

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.Semantic proximity Read ↗

Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.Semantic proximity Read ↗

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.Semantic proximity Read ↗

Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.Semantic proximity Read ↗

Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.Semantic proximity Read ↗

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 TrialSemantic proximity Read ↗

Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.Semantic proximity Read ↗

Asciminib in the treatment of chronic myeloid leukemia in chronic phase.Semantic proximity Read ↗

Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review.Semantic proximity Read ↗

Asciminib for chronic myeloid leukaemia: Next questions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.